NASDAQ:ENGN
enGene Therapeutics Inc.
enGene Therapeutics Inc. reported net income of −$117.3M in fiscal 2025. Free cash flow was −$100.7M, and the diluted share count rose 35.3%.Summary generated from enGene Therapeutics Inc.'s SEC filings. Latest annual report filed Dec 22, 2025.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−53.3%
Debt / equityn/a
Free cash flow−$100.7M
FCF marginn/a
Share count change+35.3%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a |
| Operating income | −19 | −26 | −62 | −123 |
| Net income | −24 | −100 | −55 | −117 |
| Free cash flow | −18 | −25 | −49 | −101 |
Recent filings
- 4Insider transaction report
Sep 24, 2026 - 10-QQuarterly report for the period ended Jul 31, 2026
Sep 8, 2026 - 8-KResults of operations and financial condition
Sep 8, 2026 - 8-KOther events
Aug 11, 2026 - 8-KRegulation FD disclosure
Jul 17, 2026 - 8-KDirector or officer change
Jul 16, 2026 - 8-K/AAmended costs of exit or disposal activities
Jun 18, 2026 - 4Insider transaction report
Jun 17, 2026